Jump to content

Hypoplastic left heart syndrome

From Wikipedia, the free encyclopedia
Hypoplastic left heart syndrome
Other namesCyanotic heart disease - hypoplastic left heart[1]
Illustration of heart with hypoplastic left heart syndrome
SpecialtyCardiology Edit this on Wikidata

Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect in which the left side of the heart is severely underdeveloped and incapable of supporting the systemic circulation.[2] It is estimated to account for 2-3% of all congenital heart disease.[3] Early signs and symptoms include poor feeding, cyanosis, and diminished pulse in the extremities.[4] The etiology is believed to be multifactorial resulting from a combination of genetic mutations and defects resulting in altered blood flow in the heart.[5][6][7] Several structures can be affected including the left ventricle, aorta, aortic valve, or mitral valve all resulting in decreased systemic blood flow.[8]

Diagnosis can occur prenatally via ultrasound or shortly after birth via echocardiography.[5] Initial management is geared to maintaining patency of the ductus arteriosus - a connection between the pulmonary artery and the aorta that closes shortly after birth.[9] Thereafter, a patient subsequently undergoes a three-stage palliative repair over the next few years of life.[10] The Norwood procedure is typically done within a few days of birth.[10] The Glenn procedure is typically performed at three to six months of age.[10] Finally the Fontan procedure is done sometime between the age of two and five years of age.[10]

If left untreated, patients with HLHS die within the first weeks of life while 70% of those that undergo three-staged palliative surgery reach adulthood. After surgery, children with HLHS typically experience neurodevelopmental as well as motor delay and are at an increased risk of heart failure as adults.[11][12]

Epidemiology

[edit]

HLHS occurs in an estimated 1 out of 3,841 live births in the United States, or an estimated total of 1,025 live births per year in the US.[13][14] Overall, it is estimated to make up 2-3% of all cases of congenital heart disease, and is the most common single-ventricle defect.[3] It is thought to be more common in male infants, 1.5 times as common as in female infants.[15] A recent systematic review found a slight decrease in prevalence of HLHS from 0.689/1000 in 1995–1999, to 0.475/1000 in 2010–2017.[3] This is thought to be due to improvements in prenatal detection and prenatal counseling in subsequent pregnancies.

Signs and symptoms

[edit]
Infant with cyanosis due to hypoplastic left heart syndrome

Closing of the ductus arteriosus in a heart that is severely underdeveloped on the left results in cyanosis and respiratory distress which can progress to cardiogenic shock and death. Early symptoms might include poor feeding or cyanosis that does not respond to oxygen administration. Peripheral pulses may be weak and extremities cool to the touch.[5]

HLHS often co-occurs with low birth weight and premature birth.[5]

In neonates with a small atrial septal defect, termed "restrictive", there is inadequate mixing of oxygenated and deoxygenated blood. These neonates quickly decompensate and develop acidosis and cyanosis.[5]

On EKG, right axis deviation and right ventricular hypertrophy are common, but not indicative of HLHS. Chest x-ray may show a large heart (cardiomegaly) or increased pulmonary vasculature. Neonates with HLHS do not typically have a heart murmur, but in some cases, a pulmonary flow murmur or tricuspid regurgitation murmur may be audible.[5]

Co-occurring tricuspid regurgitation or right ventricular dysfunction can cause hepatomegaly to develop.[5]

Pathogenesis

[edit]

The majority of HLHS cases are sporadic meaning they arise in patients with no family history of HLHS.[4] Some cases may have a genetic component, as HLHS has been shown to be heritable and associated with specific gene mutations.[16][17] Possible contributing factors may include intrauterine infarction, infectious changes, and a selective left ventricular cardiomyopathy.

Genetics

[edit]

Genetic loci associated with HLHS include GJA1 (connexin 43), HAND1, NKX2.5, 10q22, and 6q23.[15][18][6] There is a slight risk of recurrence in future pregnancies, estimated to be 2-4%, which increases to 25% in families with two affected children.[4] This is thought to be mediated by genetic mutations with incomplete penetrance.[15]

HLHS is also associated with several genetic syndromes, including trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), partial trisomy 9, Turner's syndrome (XO), Jacobsen syndrome (11q deletion syndrome), Holt-Oram syndrome, and Smith-Lemli-Opitz syndrome.[15][18]

Altered Blood Flow

[edit]

A popular theory termed the "no flow, no grow" hypothesis suggest that primary anatomic defects of the aortic and mitral valves lead to malformations of the left ventricle and its outflow tract.[9] These primary defects can be divided into those that lead to outflow tract obstruction or reduced left ventricular filling.[7] Outflow tract obstruction leads to left ventricular hypertrophy and reduction in the left ventricular lumen. One example of this would be in the case of aortic stenosis. Aortic stenosis that occurs during fetal development results in added stress on the left ventricle in utero. This can eventually lead to decreased perfusion through the left ventricle which is believed to inhibit ventricular growth.[19]

Pathophysiology

[edit]

At birth, the ductus arteriosus is still open, and there is higher than normal resistance to blood flow in the lungs. This allows for adequate oxygenation via mixing between the atria and a normal appearance at birth. When the ductus begins to close and pulmonary vascular resistance decreases, blood flow through the ductus is restricted and flow to the lungs is increased.[5]

In typical anatomy, the left side of the heart receives oxygen-rich blood from the lungs and pumps it to the rest of the body. Patients with HLHS can have a number of cardiac malformations that ultimately lead to a diminutive left ventricle that is unable to supply sufficient blood flow to the rest of the body.[20] There are three main anatomic variants of the disease differentiated by either stenosis or atresia of the aortic and mitral valve.[20]

Mitral atresia and aortic atresia (MA-AA) subtype is the most severe form of HLHS resulting in no blood flow entering the left ventricle at all resulting in no possibility of left ventricular output.[20] In the mitral stenosis and aortic atresia (MS-AA) subtype blood is able to fill the left ventricle, however it is unable to be supplied to the systemic circulation via the hypoplastic ascending aorta.[20] Lastly, the mildest form is the mitral stenosis and aortic stenosis (MS-AS) subtype.[20] In these patients although the left ventricle is able to supply some blood flow to the rest of the body the overall left ventricular systemic output remains inadequate.[20]

In all of these cases blood is unable to be pumped to the rest of the body by the left ventricle. The neonate is reliant on blood flowing through an atrial septal defect to mix oxygenated and deoxygenated blood, and on a patent ductus arteriosus to allow blood to reach the aorta and the systemic circulation via the right ventricle. This is what defines HLHS as a "single ventricle" defect.[15]

Due to the underdevelopment of the left side of the heart in utero, the increased afterload causes hypertension of the left atrium, pulmonary edema, and therefore lung damage to the fetus before birth.[19]

Diagnosis

[edit]

Hypoplastic left heart syndrome can be diagnosed prenatally or after birth via echocardiography. Typical findings include a small left ventricle and aorta, abnormalities of the mitral and aortic valves, retrograde flow in the transverse arch of the aorta, and left-to-right flow between the atria. It is often recognized during the second trimester of pregnancy, between 18 and 24 weeks' gestation.[5]

Chest x-ray may also be utilized in the diagnosis of hypoplastic left heart syndrome, and typically shows an enlarged cardiac silhouette along with signs pulmonary hypertension. Blood work and genetic testing remain of high importance as well, and should include a complete blood count, electrolytes, lactate, and arterial blood gas to evaluate acid-base status and oxygenation. Genetic testing may be beneficial to obtain and has been associated with multiple chromosomal abnormalities including Turner, DiGeorge, and Down syndrome.[21]

Management

[edit]

Medical

[edit]

Without life-prolonging interventions, HLHS is fatal, but with intervention, an infant may survive. A cardiothoracic surgeon may perform a series of operations or a full heart transplant. While surgical intervention has emerged as the standard of care in the United States, other national health systems, notably in France, approach diagnosis of HLHS in a more conservative manner, with an emphasis on termination of pregnancy or compassionate care after delivery.[8]

Before surgery, the ductus must be kept open to allow blood-flow using medication containing prostaglandin.[9] Air with less oxygen than normal is used for infants with hypoplastic left heart syndrome. These low oxygen levels increases the pulmonary vascular resistance (PVR) and thus improve blood flow to the rest of the body due to the greater pressure difference between the lungs and body. Achieving oxygen levels below atmosphere requires the use of inhaled nitrogen.[22] Nitric oxide is a potent pulmonary vasodilator, and thus reduces PVR and improves venous return. Any factor that increases PVR will impede right-sided flow.[23][24]

Surgical

[edit]

Surgical operations to assist with hypoplastic left heart are complex and need to be individualized for each patient. A cardiologist must assess all medical and surgical options on a case-by-case basis.[citation needed]

Currently, infants undergo either the staged reconstructive surgery (Norwood or Sano procedure within a few days of birth, Glenn or Hemi-Fontan procedure at 3 to 6 months of age, and the Fontan procedure at 1 1/2 to 5 years of age) or cardiac transplantation.[10] Current expectations are that 70% of those with HLHS may reach adulthood.[18] Many studies show that the higher the volume (number of surgeries performed) at a hospital, the lower the mortality (death) rate.[25][26] Factors that increase an infant's risk include lower birth weight, additional congenital anomalies, a genetic syndrome or those with a highly restrictive atrial septum.[27] For patients without these additional risk factors, 5 year survival now approaches 80%.[27] Studies show that about 75% of those children who survive surgery show developmental delays in one or more areas, such as motor, cognitive, or language impairments, with about a third of single-ventricle children without a genetic syndrome having significant impairments.[28] Current research focuses on charting the connections between neurodevelopment injuries, surgical and intensive care procedures, and genetic susceptibility with the goal of modifying interventions that impair neurodevelopmental and psychosocial outcomes.[29] An alternative to the traditional Norwood is the Hybrid procedure.[30]

Some physicians offer compassionate care, instead of the surgeries, which results in the child's death, usually within 2 weeks of birth. Compassionate care is overseen by a physician, and may be carried out either in the hospital or at home. However, due to the vast improvement of surgical intervention, with many hospitals achieving over 90% survival, there is debate on whether or not compassionate care should still be offered to families.[31] A study in 2003 concluded that a selection of physicians who are experts in the care of children with HLHS were evenly split when asked what they would do if their own children were born with HLHS, with 1/3 stating that they would choose surgery, 1/3 stating that they would choose palliative (compassionate) treatment without surgery, and 1/3 stating that they are uncertain which choice they would make.[32]

The three-stage procedure is a palliative procedure (not a cure), as the child's circulation is made to work with only two of the heart's four chambers.[citation needed]

Norwood procedure

Norwood procedure

[edit]

The first step is the Norwood procedure.[33] In this procedure, the right ventricle is used to pump blood into the systemic circulation. Since the right ventricle is no longer directly pumping blood to the lungs, a shunt is required in order to pass deoxygenated blood through the lungs. Either the subclavian artery can be connected to the pulmonary circulation (Blalock-Taussig shunt), or a shunt is made directly from the right ventricle to the pulmonary circulation (Sano shunt). The narrow aorta is enlarged using a patch to improve blood flow to the body.[34]

During this time the baby may be medically fragile and have feeding problems because the heart is working very hard. There is a considerable degree of venous mixing in the right ventricle, leading to lower oxygen saturation. In addition, both the Blalock-Taussig and the Sano shunts expose the lungs to systemic arterial pressures, leading to long-term pulmonary hypertension and, eventually, heart failure.[33]

Hybrid procedure

[edit]

The Hybrid procedure may be used in place of the Norwood.[33][35][36] The Hybrid procedure does not necessitate the use of heart-lung bypass or performing a sternotomy. Instead of a six-hour surgery, the Hybrid typically takes one to two hours. In this procedure, a stent is placed in the ductus arteriosus to maintain its patency, and bands are placed over both the left and right pulmonary artery branches to limit pressure and over-circulation to the lungs.[37] Outcomes with the Hybrid approach are comparable to those with the Norwood.[38]

Glenn procedure

[edit]

The second stage—the bidirectional Glenn or Hemi-Fontan (see also Kawashima procedure)—relieves some of the problems introduced by Stage I palliation.[33] In this operation, the superior vena cava is ligated from the heart and connected to the pulmonary circulation. At this time, the Blalock-Taussig or Sano shunt is taken down. The lungs are no longer exposed to systemic arterial pressures, but much lower venous pressures. Although venous blood from the upper half of the body is no longer mixing with oxygenated blood in the right ventricle, there is still venous mixing from the lower half of the body, leading to some degree of oxygen desaturation.[33]

Fontan procedure

[edit]

The final procedure, the Fontan procedure, completes the repair of the hypoplastic left heart.[33] Although there are several variations, the functional effect is to redirect venous blood from the lower body (through the inferior vena cava) away from the right atrium to the pulmonary artery. This should eliminate any mixing of oxygenated and deoxygenated blood in the right ventricle. The right ventricle performs the traditional job of the left, supplying the body with oxygenated blood, while the passive systemic venous pressure performs the traditional job of the right, passing deoxygenated blood to the lungs.[33]

Fetal surgery
[edit]

Interventions performed during fetal development are under investigation. When signs of HLHS are detected prenatally via ultrasound, a percutaneous procedure involving the insertion of a balloon catheter can open the atrial septal defect to prevent left atrial hypertension and promote improved heart development.[39][40]

Prognosis

[edit]

95% of untreated infants with HLHS die in the first weeks of life.[5]

Early survival has improved since the introduction of the Norwood procedure.[18] Since there are no long-term studies of HLHS adults, statistics are usually derived from post-Fontan patients; it is estimated that 70% of HLHS patients may reach adulthood.[18]

Prognosis is dependent upon the health of the child, as there is an increased demand on respiratory and heart rate in infants during common childhood illnesses. This fragile population has little cardiac reserve to accommodate these demands and provide hemodynamic stability during illnesses.[41]

Children with HLHS and other comparable single-ventricle conditions, as a group, have poorer neurodevelopmental outcomes than their healthy peers. Deficits in language, executive functioning, and higher rates of anxiety and depression disorders have been demonstrated.[42] Some of these outcomes may be a consequence of genetic factors associated with HLHS, and others may be modifiable through changes to procedures and to the healthcare environment. There is an emerging clinical consensus around the importance of continuous neurodevelopmental surveillance from the earliest years into adulthood.[11][43] Additionally, a recent meta-analysis comparing twenty-two studies showed that 64.7% of the studies reported delayed motor development in children with single ventricle physiologies, such as hypoplastic left heart syndrome.[12]

As is true for patients with other types of heart defects involving malformed valves,[44] HLHS patients run a high risk of endocarditis, and must be monitored by a cardiologist for the rest of their lives to check on their heart function.[citation needed]

Heart transplantation may be indicated, typically after Fontan completion.[18] One multi-center study (of patients undergoing the Fontan from 1993 to 2001) reported a 76% 1-year survival rate in patients who survived to transplant.[45]

Future of stem cell therapies

[edit]

A systematic review found 23 articles, published since 2010, as well as nine relevant clinical trials related to congenital heart disease and recent advances in stem cell therapies.[46] Pre-clinical research has focused on several types of stem cells including: mesenchymal stem cells (MSCs), autologous umbilical cord blood cells, c-kit+ cardiac stem cells, and neonatal thymus mesenchymal stem cells.[46] These cell types have shown the ability to differentiate into cardiac tissue making them ideal for cardiac regenerative therapy.  The first use of autologous umbilical cord blood cells was done at the Mayo Clinic in 2015 and was found to increase right ventricular function in the patient after their procedure.[46] The first use of cardiac progenitor cells occurred in the Transcoronary Infusion of Cardiac Progenitor Cells in Patients with Single-Ventricle Physiology (TICAP) Trail of 2011.[46]

Ongoing trials

[edit]

There are several ongoing studies testing the feasibility and efficacy of stem cell therapies for single ventricle diseases such as HLHS.[46] These trials focus on what are the most effective stem cells, what is the best timing in the 3-stage repair, and what is the optimal delivery method.

  • Phase IIb trial testing the efficacy of intramyocardial injections umbilical cord blood cells during Stage II (Glenn) repair.[47]
  • Phase I trial testing the efficacy of autologous cord blood cell infusion during Stage 1 (Norwood) repair within two-to-three days of birth.[48]
  • The ELPIS trial is a phase I/IIb open pilot testing the efficacy and safety of intramyocardial donor human mesenchymal stem cell injections in patients during Stage 2 (Glenn) and Stage 3 (Fontan) repairs.[49]
  • Phase I trial testing the efficacy of umbilical cord blood intramyocardial injections during Stage 2 (Glenn) repair.[50]
  • The PERSEUS study is a phase II trial testing the efficacy of intracoronary infusions of cardiac progenitor cells and evaluating function 3-months post-treatment.[51]
  • APOLLON study is a phase III clinical trial testing the efficacy and safety of intracoronary injections of autologous cardiac stem cells during Stage 2 (Glenn) or Stage 3 (Fontan) repair.[52]
  • CHILD Study is a phase I clinical trial testing the feasibility and safety of intramyocardial injections of c-kit+ cells during Stage 2 (Glenn) repair.[53]

It is important to keep in mind that patients with HLHS are at increased risk of developing heart failure as adults. It remains unknown if these potential therapies would reduce the future risk of heart failure in these patients.

References

[edit]
  1. ^ "Hypoplastic left heart syndrome: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 28 May 2019.
  2. ^ Tchervenkov, C. I; Jacobs, J. P; Weinberg, P. M; Aiello, V. D; Béland, M. J; Colan, S. D; Elliott, M. J; Franklin, R. C; Gaynor, J. W; Krogmann, O. N; Kurosawa, H; Maruszewski, B; Stellin, G (2006). "The nomenclature, definition and classification of hypoplastic left heart syndrome". Cardiology in the Young. 16 (4): 339–368. doi:10.1017/s1047951106000291. PMID 16839428.
  3. ^ a b c Liu, Yingjuan; Chen, Sen; Zühlke, Liesl; Black, Graeme C.; Choy, Mun-Kit; Li, Ningxiu; Keavney, Bernard D. (2019-04-01). "Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies". International Journal of Epidemiology. 48 (2): 455–463. doi:10.1093/ije/dyz009. ISSN 1464-3685. PMC 6469300. PMID 30783674.
  4. ^ a b c Barron, D. J., Kilby, M. D., Davies, B., Wright, J. G., Jones, T. J., & Brawn, W. J. (2009). "Hypoplastic left heart syndrome". The Lancet. 374 (9689): 551–564. doi:10.1016/s0140-6736(09)60563-8. PMID 19683641. S2CID 3285769.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ a b c d e f g h i j Fulton, David R. (October 26, 2017). "Hypoplastic left heart syndrome". Up To Date. Retrieved 2017-11-30.
  6. ^ a b Hinton, R. B., Martin, L. J., Rame-Gowda, S., Tabangin, M. E., Cripe, L. H., & Benson, D. W. (2009). "Hypoplastic left heart syndrome links to chromosomes 10q and 6q and is genetically related to bicuspid aortic valve". Journal of the American College of Cardiology. 53 (12): 1065–1071. doi:10.1016/j.jacc.2008.12.023. PMC 2703749. PMID 19298921.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ a b Kritzmire, Stacy M.; Cossu, Anne E. (2021), "Hypoplastic Left Heart Syndrome", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32119463, retrieved 2021-11-12
  8. ^ a b Noseda C, Mialet-Marty T, Basquin A (April 2012). "Hypoplasies sévères du ventricule gauche : soins palliatifs après un diagnostic prénatal". Archives de Pédiatrie. 19 (4): 374–380. doi:10.1016/j.arcped.2012.01.022. PMID 22397767.
  9. ^ a b c Crucean, A.; Alqahtani, A.; Barron, D. J.; Brawn, W. J.; Richardson, R. V.; O’Sullivan, J.; Anderson, R. H.; Henderson, D. J.; Chaudhry, B. (2017-08-10). "Re-evaluation of hypoplastic left heart syndrome from a developmental and morphological perspective". Orphanet Journal of Rare Diseases. 12 (1): 138. doi:10.1186/s13023-017-0683-4. ISSN 1750-1172. PMC 5551014. PMID 28793912.
  10. ^ a b c d e Hypoplastic Left Heart Syndrome (HLHS) | The Children's Hospital of Philadelphia
  11. ^ a b Marino, Bradley S.; Lipkin, Paul H.; Newburger, Jane W.; Peacock, Georgina; Gerdes, Marsha; Gaynor, J. William; Mussatto, Kathleen A.; Uzark, Karen; Goldberg, Caren S. (2012-08-28). "Neurodevelopmental Outcomes in Children With Congenital Heart Disease: Evaluation and Management: A Scientific Statement From the American Heart Association". Circulation. 126 (9): 1143–1172. doi:10.1161/CIR.0b013e318265ee8a. ISSN 0009-7322. PMID 22851541.
  12. ^ a b Sprong, Maaike C. A.; Broeders, Willem; van der Net, Janjaap; Breur, Johannes M. P. J.; de Vries, Linda S.; Slieker, Martijn G.; van Brussel, Marco (2021-10-01). "Motor Developmental Delay After Cardiac Surgery in Children With a Critical Congenital Heart Defect: A Systematic Literature Review and Meta-analysis". Pediatric Physical Therapy. 33 (4): 186–197. doi:10.1097/PEP.0000000000000827. ISSN 1538-005X. PMID 34618742. S2CID 238255373.
  13. ^ "Hypoplastic Left Heart Syndrome Facts | Congenital Heart Defects". Centers for Disease Control and Prevention. 2017-10-26. Retrieved 2017-11-30.
  14. ^ Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A; National Birth Defects Prevention Network. (2010). "Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006". Birth Defects Research Part A: Clinical and Molecular Teratology. 88 (12): 1008–16. doi:10.1002/bdra.20735. PMID 20878909.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ a b c d e Fulton, David R. (October 26, 2017). "Hypoplastic left heart syndrome". Up To Date. Retrieved 2017-11-30.
  16. ^ Hinton, R. B., Martin, L. J., Tabangin, M. E., Mazwi, M. L., Cripe, L. H., & Benson, D. W. (2007). "Hypoplastic left heart syndrome is heritable". Journal of the American College of Cardiology. 50 (16): 1590–1595. doi:10.1016/j.jacc.2007.07.021. PMID 17936159.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH (2001). "Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE)". Mutat. Res. 479 (1–2): 173–86. Bibcode:2001MRFMM.479..173D. doi:10.1016/S0027-5107(01)00160-9. PMID 11470490.
  18. ^ a b c d e f Feinstein, JA; Benson, DW; Dubin, AM; Cohen, MS; Maxey, DM; Mahle, WT; Pahl, E; Villafañe, J; Bhatt, AB; Peng, LF; Johnson, BA; Marsden, AL; Daniels, CJ; Rudd, NA; Caldarone, CA; Mussatto, KA; Morales, DL; Ivy, DD; Gaynor, JW; Tweddell, JS; Deal, BJ; Furck, AK; Rosenthal, GL; Ohye, RG; Ghanayem, NS; Cheatham, JP; Tworetzky, W; Martin, GR (3 January 2012). "Hypoplastic left heart syndrome: current considerations and expectations". Journal of the American College of Cardiology. 59 (1 Suppl): S1–42. doi:10.1016/j.jacc.2011.09.022. PMC 6110391. PMID 22192720.
  19. ^ a b Schidlow, David N.; Freud, Lindsay; Friedman, Kevin; Tworetzky, Wayne (2017). "Fetal interventions for structural heart disease". Echocardiography. 34 (12): 1834–1841. doi:10.1111/echo.13667. ISSN 1540-8175. PMID 29287139. S2CID 12087225.
  20. ^ a b c d e f Tchervenkov, C. I.; Jacobs, M. L.; Tahta, S. A. (April 2000). "Congenital Heart Surgery Nomenclature and Database Project: hypoplastic left heart syndrome". The Annals of Thoracic Surgery. 69 (4 Suppl): S170–179. doi:10.1016/s0003-4975(99)01283-7. ISSN 0003-4975. PMID 10798427.
  21. ^ Kritzmire, Stacy M.; Cossu, Anne E. (2024), "Hypoplastic Left Heart Syndrome", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32119463, retrieved 2024-09-10
  22. ^ Green A, Pye S, Yetman AT (August 2002). "The physiologic basis for and nursing considerations in the use of subatmospheric concentrations of oxygen in HLHS". Advances in Neonatal Care. 2 (4): 177–86. doi:10.1053/adnc.2002.33542. PMID 12881932.
  23. ^ Khambadkone S.; Li J.; De Leval M. R.; Cullen S.; Deanfield J. E.; Redington A. N. (2003). "Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation". Circulation. 107 (25): 3204–3208. doi:10.1161/01.cir.0000074210.49434.40. PMID 12821557.
  24. ^ Norwood W. I. (1991). "Hypoplastic left heart syndrome. The". Annals of Thoracic Surgery. 52 (3): 688–695. doi:10.1016/0003-4975(91)90978-y. PMID 1898174.
  25. ^ McHugh, KE; Hillman, DG; Gurka, MJ; Gutgesell, HP (Jan–Feb 2010). "Three-stage palliation of hypoplastic left heart syndrome in the University HealthSystem Consortium". Congenital Heart Disease. 5 (1): 8–15. doi:10.1111/j.1747-0803.2009.00367.x. PMID 20136852.
  26. ^ Hirsch, JC; Gurney, JG; Donohue, JE; Gebremariam, A; Bove, EL; Ohye, RG (July 2008). "Hospital mortality for Norwood and arterial switch operations as a function of institutional volume". Pediatric Cardiology. 29 (4): 713–7. doi:10.1007/s00246-007-9171-2. PMID 18080151. S2CID 23456242.
  27. ^ a b Vojtovič, P.; Tláskal, T.; Gebauer, R.; Reich, O.; Chaloupecký, V.; Tomek, V.; Krupičková, S.; Matějka, T.; Hecht, P. (December 2014). "Long-term results of children operated for hypoplastic left heart syndrome in Children's Heart Centre". Cor et Vasa. 56 (6): e449–e455. doi:10.1016/j.crvasa.2014.07.006. ISSN 0010-8650.
  28. ^ Mussatto, Kathleen A.; Hoffmann, Raymond G.; Hoffman, George M.; Tweddell, James S.; Bear, Laurel; Cao, Yumei; Brosig, Cheryl (2014). "Risk and prevalence of developmental delay in young children with congenital heart disease". Pediatrics. 133 (3): e570–577. doi:10.1542/peds.2013-2309. ISSN 1098-4275. PMC 3934337. PMID 24488746.
  29. ^ Wernovsky, Gil; Licht, Daniel J. (2016). "Neurodevelopmental Outcomes in Children with Congenital Heart Disease – What can we impact?". Pediatric Critical Care Medicine. 17 (8 Suppl 1): S232–S242. doi:10.1097/PCC.0000000000000800. ISSN 1529-7535. PMC 4975480. PMID 27490605.
  30. ^ Yabrodi, Mouhammad; Mastropietro, Christopher W. (2016-10-04). "Hypoplastic left heart syndrome: from comfort care to long-term survival". Pediatric Research. 81 (1–2): 142–149. doi:10.1038/pr.2016.194. ISSN 0031-3998. PMC 5313512. PMID 27701379.
  31. ^ Wernovsky, Gil (1 September 2008). "The Paradigm Shift Toward Surgical Intervention for Neonates With Hypoplastic Left Heart Syndrome". Archives of Pediatrics & Adolescent Medicine. 162 (9): 849–54. doi:10.1001/archpedi.162.9.849. PMID 18762602.
  32. ^ Kon, Alexander A.; Ackerson, Lynn; Lo, Bernard (31 May 2003). "Choices physicians would make if they were the parents of a child with hypoplastic left heart syndrome". The American Journal of Cardiology. 91 (12): 1506–1509. doi:10.1016/S0002-9149(03)00412-0. PMID 12804748.
  33. ^ a b c d e f g Feinstein, Jeffrey A.; Benson, D. Woodrow; Dubin, Anne M.; Cohen, Meryl S.; Maxey, Dawn M.; Mahle, William T.; Pahl, Elfriede; Villafañe, Juan; Bhatt, Ami B. (Jan 2012). "Hypoplastic Left Heart Syndrome". Journal of the American College of Cardiology. 59 (1): S1–S42. doi:10.1016/j.jacc.2011.09.022. PMC 6110391. PMID 22192720.
  34. ^ "new norwood.gif". Archived from the original on November 24, 2010.
  35. ^ Murphy, Michael O.; Bellsham-Revell, Hannah; Morgan, Gareth J.; Krasemann, Thomas; Rosenthal, Eric; Qureshi, Shakeel A.; Salih, Caner; Austin, Conal B.; Anderson, David R. (2015). "Hybrid Procedure for Neonates With Hypoplastic Left Heart Syndrome at High-Risk for Norwood: Midterm Outcomes". The Annals of Thoracic Surgery. 100 (6): 2286–2292. doi:10.1016/j.athoracsur.2015.06.098. PMID 26433522.
  36. ^ Chauhan, Monika; Mastropietro, Christopher W. (2014). "Hypoplastic Left Heart Syndrome in the Emergency Department: An Update". The Journal of Emergency Medicine. 46 (2): e51–e54. doi:10.1016/j.jemermed.2013.08.061. PMID 24188609.
  37. ^ "Children's Hospital Boston | Pediatric Views". Archived from the original on 2012-02-29. Retrieved 2010-05-14.
  38. ^ Galantowicz M, Cheatham JP, Phillips A, et al. (June 2008). "Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve". Ann. Thorac. Surg. 85 (6): 2063–70, discussion 2070–1. doi:10.1016/j.athoracsur.2008.02.009. PMID 18498821.
  39. ^ Sood, Vikram; Zampi, Jeffrey D.; Romano, Jennifer C. (6 April 2020). "Hypoplastic left heart syndrome with an intact atrial septum". JTCVS Open. 1: 51–56. doi:10.1016/j.xjon.2020.03.001. PMC 9390260. PMID 36003193.
  40. ^ Cunningham, F. Gary; Leveno, Kenneth J.; Bloom, Steven L.; Spong, Catherine Y.; Dashe, Jodi S.; Hoffman, Barbara L.; Casey, Brian M.; Sheffield, Jeanne S. (2013). "Fetal Imaging". Williams Obstetrics (24 ed.). New York, NY: McGraw-Hill Education.
  41. ^ Nieves, Jo Ann; Uzark, Karen; Rudd, Nancy A.; Strawn, Jennifer; Schmelzer, Anne; Dobrolet, Nancy (2017-04-01). "Interstage Home Monitoring After Newborn First-Stage Palliation for Hypoplastic Left Heart Syndrome: Family Education Strategies". Critical Care Nurse. 37 (2): 72–88. doi:10.4037/ccn2017763. ISSN 0279-5442. PMID 28365652. S2CID 39147698.
  42. ^ White, Brian R.; Rogers, Lindsay S.; Kirschen, Matthew P. (2019). "Recent advances in our understanding of neurodevelopmental outcomes in congenital heart disease". Current Opinion in Pediatrics. 31 (6): 783–788. doi:10.1097/MOP.0000000000000829. ISSN 1040-8703. PMC 6852883. PMID 31693588.
  43. ^ Gurvitz, Michelle; Burns, Kristin M.; Brindis, Ralph; Broberg, Craig S.; Daniels, Curt J.; Fuller, Stephanie M.P.N.; Honein, Margaret A.; Khairy, Paul; Kuehl, Karen S. (2016-04-26). "Emerging Research Directions in Adult Congenital Heart Disease: A Report from a National Heart, Lung, and Blood Institute/Adult Congenital Heart Association Working Group". Journal of the American College of Cardiology. 67 (16): 1956–1964. doi:10.1016/j.jacc.2016.01.062. ISSN 0735-1097. PMC 4846980. PMID 27102511.
  44. ^ "Endocarditis: Risk factors". MayoClinic.com. Retrieved 2007-10-23.
  45. ^ Taylor, D. O., Stehlik, J., Edwards, L. B., Aurora, P., Christie, J. D., Dobbels, F., ... & Hertz, M. I. (2009). "Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report—2009". The Journal of Heart and Lung Transplantation. 28 (10): 1007–1022. doi:10.1016/j.healun.2009.08.014. PMID 19782283.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  46. ^ a b c d e Brown, Matthew A.; Rajamarthandan, Siva; Francis, Berline; O'Leary-Kelly, Meghan K.; Sinha, Pranava (January 2020). "Update on stem cell technologies in congenital heart disease". Journal of Cardiac Surgery. 35 (1): 174–179. doi:10.1111/jocs.14312. ISSN 1540-8191. PMID 31705822. S2CID 207963021.
  47. ^ Timothy J. Nelson (2021-05-12). "Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)". {{cite journal}}: Cite journal requires |journal= (help)
  48. ^ Pepe, Salvatore (2020-08-31). "Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation". Murdoch Childrens Research Institute. {{cite journal}}: Cite journal requires |journal= (help)
  49. ^ Longeveron Inc. (2021-09-24). "Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)". {{cite journal}}: Cite journal requires |journal= (help)
  50. ^ Timothy J. Nelson (2021-03-08). "Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome". {{cite journal}}: Cite journal requires |journal= (help)
  51. ^ Oh, Hidemasa (2017-01-03). "Phase 2 Study of Intracoronary Infusion of Cardiac Progenitor Cells in Patients With Univentricular Heart Disease". Okayama University, Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. {{cite journal}}: Cite journal requires |journal= (help)
  52. ^ Japan Regenerative Medicine Co., Ltd. (2020-11-15). "Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study". {{cite journal}}: Cite journal requires |journal= (help)
  53. ^ University of Miami (2021-10-05). "Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study". {{cite journal}}: Cite journal requires |journal= (help)
[edit]
Hypoplastic left heart syndrome video by Osmosis
Wikimedia Commons has media related to Hypoplastic left heart syndrome.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hypoplastic_left_heart_syndrome&oldid=1250003787"